Typhoid Fever Vaccines

Global Typhoid Fever Vaccines Market to Reach US$1.0 Billion by 2030

The global market for Typhoid Fever Vaccines estimated at US$430.6 Million in the year 2024, is expected to reach US$1.0 Billion by 2030, growing at a CAGR of 15.7% over the analysis period 2024-2030. Live Attenuated Vaccine, one of the segments analyzed in the report, is expected to record a 16.9% CAGR and reach US$510.0 Million by the end of the analysis period. Growth in the Capsular Polysaccharide Vaccine segment is estimated at 16.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$117.3 Million While China is Forecast to Grow at 21.0% CAGR

The Typhoid Fever Vaccines market in the U.S. is estimated at US$117.3 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$226.6 Million by the year 2030 trailing a CAGR of 21.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.4% and 14.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.5% CAGR.

Global "Typhoid Fever Vaccines" Market – Key Trends & Drivers Summarized

Why Is The Global Fight Against Typhoid Gaining Unprecedented Momentum?

Over the past decade, the fight against typhoid fever has undergone a major transformation, especially due to renewed attention from global health authorities and the development of novel typhoid fever vaccines. The increasing burden of typhoid, particularly in low- and middle-income countries (LMICs), has triggered significant investments in preventive healthcare measures. According to the World Health Organization (WHO), typhoid fever affects between 11–21 million people globally each year, with approximately 128,000 to 161,000 deaths. Vaccines such as Typbar-TCV (Typhoid Conjugate Vaccine) have emerged as critical interventions due to their long-lasting immunity, applicability to younger age groups, and lower risk of adverse effects. What’s more, countries like Pakistan and Zimbabwe have rolled out mass immunization campaigns, which have demonstrated both efficacy and cost-efficiency. As water and sanitation improvements alone are insufficient in high-burden regions, governments are integrating vaccine programs into national immunization schedules. Moreover, the expanded support from organizations like Gavi, the Vaccine Alliance, is streamlining the financing and distribution of these vaccines, accelerating adoption in the regions most in need.

How Is Innovation Shaping The Efficacy And Reach Of Typhoid Fever Vaccines?

The evolution of typhoid vaccines from traditional live attenuated or inactivated types to conjugate vaccines has marked a pivotal advancement in terms of coverage, durability, and age-appropriate administration. Traditional vaccines like Ty21a and Vi polysaccharide had limitations in terms of age restriction (usually ineffective in children under 2) and shorter immunity. The new-generation Typhoid Conjugate Vaccines (TCVs), however, can be administered to children as young as 6 months and provide protection for up to 5 years or longer. This development has significant implications for pediatric immunization strategies in endemic regions. Furthermore, global clinical trials are exploring multi-pathogen conjugate vaccines that combine typhoid protection with other enteric diseases, such as paratyphoid and invasive non-typhoidal salmonella (iNTS). These innovations are particularly critical as antimicrobial resistance (AMR) continues to rise in Salmonella Typhi strains, rendering traditional antibiotic therapies less effective. As a result, preventive immunization is gaining traction as the most sustainable approach to typhoid control. Additionally, biotech firms are investing in thermostable formulations to mitigate cold-chain dependency, which remains a challenge in remote or under-resourced settings.

Can Strategic Policies And International Collaborations Bridge The Accessibility Gap?

As the global healthcare ecosystem becomes more interconnected, the role of policy frameworks and cross-border partnerships is proving vital to the proliferation of typhoid fever vaccines. The WHO`s prequalification of TCVs has opened the doors for procurement by United Nations agencies, facilitating widespread implementation. Meanwhile, Gavi’s financial support for eligible countries has made vaccines affordable and accessible, particularly in sub-Saharan Africa and South Asia. These interventions are complemented by domestic policy reforms where ministries of health are incorporating typhoid vaccines into routine immunization schedules. Moreover, joint efforts among NGOs, health ministries, and international donors are focusing on strengthening surveillance systems, community awareness, and cold-chain infrastructure to ensure seamless distribution. Global initiatives such as the Coalition against Typhoid are also amplifying advocacy and fostering a data-driven approach to monitoring outbreaks and vaccine impact. Furthermore, the COVID-19 pandemic has highlighted the urgency of bolstering immunization systems, with governments increasingly recognizing the role of preventive vaccination as a tool for broader health resilience. Such a shift in perspective is driving new funding channels and accelerating regulatory approvals in historically underrepresented regions.

What’s Powering The Surge In Demand For Typhoid Vaccines Around The World?

The growth in the typhoid fever vaccines market is driven by several factors that are reshaping public health priorities and advancing immunization coverage globally. Firstly, the rise in multi-drug resistant (MDR) and extensively drug-resistant (XDR) typhoid strains has drastically limited treatment options, positioning vaccines as a primary line of defense. Secondly, a marked increase in urbanization without corresponding improvements in water and sanitation infrastructure in many LMICs has maintained high transmission rates, sustaining demand for preventive solutions. Thirdly, greater political commitment to combat enteric diseases, especially in Asia and Africa, has translated into comprehensive immunization campaigns and increased healthcare budgets. Additionally, improved diagnostic surveillance has enabled better identification of hotspots, allowing targeted vaccine deployment. From a technological standpoint, the development of pediatric-compatible, single-dose TCVs with extended efficacy has simplified immunization logistics and expanded age group eligibility. Moreover, rising health literacy and community engagement in vaccine initiatives have improved public receptivity, reducing vaccine hesitancy. Lastly, the growing presence of global and regional vaccine manufacturers has increased supply chain reliability, fostering a competitive environment that encourages innovation and price reduction—two key levers in expanding vaccine accessibility across diverse geographies.

SCOPE OF STUDY:

The report analyzes the Typhoid Fever Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine, Other Types); Administration Route (Oral, Injection); End-Use (Hospitals & Clinics, Specialty Centers, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

• Bavarian Nordic A/S
• Bharat Biotech International Ltd.
• Biological E. Limited
• Bio-Med Pvt. Ltd.
• Cadila Healthcare Ltd. (Zydus Lifesciences)
• Chiron Behring Vaccines Pvt. Ltd.
• Emergent BioSolutions Inc.
• GlaxoSmithKline plc
• Haffkine Bio-Pharmaceutical Corp. Ltd.
• Incepta Vaccine Ltd.
• Indian Immunologicals Ltd.
• Merck & Co., Inc.
• Panacea Biotec Ltd.
• PaxVax, Inc.
• Pfizer Inc.
• Prokarium Ltd.
• Sanofi Pasteur
• Serum Institute of India Pvt. Ltd.
• Shanta Biotechnics Ltd.
• SK bioscience Co., Ltd.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.